Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts

Executive Summary

Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.


Related Content

Biosimilar Trends: What 2017 May Have In Store
Shire Exits Biosimilars, Streamlines Oncology Business
Resilient US Rebif, Gonal-f Q2 Sales Allow German Merck To Up Forecast
German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space
Merck KGaA Returns PKU Drugs To BioMarin To Focus On Cancer
Pfizer sides with Merck KGaA on PD-L1; AZ deal out for good?
Merck KGaA expands chemicals business with $17bn Sigma-Aldrich buy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts